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Vitamin A and its metabolite retinoic acid (RA) are essential elements for normal lung development and the
differentiation of lung epithelial cells. We previously showed that RA rapidly activated cyclic AMP response
element-binding protein (CREB) in a nonclassical manner in normal human tracheobronchial epithelial
(NHTBE) cells. In the present study, we further demonstrated that this nonclassical signaling of RA on the
activation of CREB plays a critical role in regulating the expression of airway epithelial cell differentiation
markers, the MUC2, MUC5AC, and MUC5B genes. We found that RA rapidly activates the protein kinase C
isozyme and transmits the activation signal to CREB via the Raf/MEK/extracellular signal-regulated kinase/
p90 ribosomal S6 kinase (RSK) pathway. Activated RSK translocated from the cytoplasm to the nucleus, where
it phosphorylates CREB. Activated CREB then binds to a cis-acting replication element motif on the promoter
(at nucleotides [nt] 878 to 871) of the MUC5AC gene. The depletion of CREB using small interfering RNA
abolished not only the RA-induced MUC5AC but also RA-induced MUC2 and MUC5B. Taken together, our
findings demonstrate that CREB activation via this nonclassical RA signaling pathway may play an important
role in regulating the expression of mucin genes and mediating the early biological effects of RA during normal
mucous differentiation in NHTBE cells.
Mucus hyperproduction caused by respiratory disorders
such as rhinitis, sinusitis, asthma, cystic fibrosis, and chronic
obstructive pulmonary disease is currently incurable. Under-
standing the mechanisms of mucin gene regulation may lead to
a new therapeutic opportunity for treating these disorders.
Mucins, the major protein components of airway mucus, are
high-molecular-mass glycoproteins produced by the epithelia
of the respiratory tract and contribute to the viscoelastic prop-
erties of secreted mucus. To date, 18 human mucin genes have
been cloned; at least 12 of them are expressed as mRNA in the
lower respiratory tract (51). MUC5AC, which is a product of
the goblet cells, is the major airway secretory mucin (23).
MUC5AC gene expression is known to be regulated by retinoic
acids (RAs) (31, 32).
RA, which is a metabolite of vitamin A, has an essential role
in the development and maintenance of mucociliary differen-
tiation of the epithelium in the conducting airways (18, 20, 21).
When normal human tracheobronchial epithelial (NHTBE)
cells are cultured in medium deficient in RAs, they undergo
squamous differentiation; the addition of RAs restores mucous
differentiation (31, 32) and induces mucin gene expression. We
previously showed that RA receptor  (RAR) played an
important role in the induction of expression of the mucin
genes MUC2, MUC5AC, and MUC5B and mucous cell differ-
entiation of bronchial epithelial cells by RA (31). Unlike this
genetic event, an early effect of RA on mucociliary differenti-
ation of bronchial epithelial cells is the nongenomic activation
of cyclic AMP (cAMP) response element (CRE)-binding pro-
tein (CREB), as we previously demonstrated that RA rapidly
activated a CREB transcription factor without using its canon-
ical RAR/retinoid X receptors (RXRs) (1).
The CREB family of transcription factors plays critical roles
in controlling cell growth, survival, and cell cycle progression
and determining the fate of many cell types (11, 26, 34, 35, 50).
Studies have shown that CREB is important for the prolifer-
ation and differentiation of neuronal cells (9, 35, 59), vascular
smooth muscle cells (28), adipocytes (49), thyrocytes (42), Ser-
toli cells (53), pancreatic beta cells (27), and hematopoietic
cells (47). CREBs recognize the specific DNA sequence 5-T
GACGTCA-3, known as the CRE, in the transcription regu-
latory regions of many cAMP-regulated genes (8, 25, 38, 40,
61) with cell type specificity (5). Studies have shown that nu-
merous kinases are involved in the activation of CREB in
response to various extracellular stimuli (e.g., growth factors
and stress signals) via diverse signaling pathways (28, 35, 55)
including protein kinase A (PKA) (7, 15), protein kinase C
(PKC) (64), p90 ribosomal S6 kinase 1/2 (RSK1/2) (63), mito-
gen- and stress-activated protein kinase 1 (10), mitogen-acti-
vated protein kinase (MAPK)-activated protein 2 kinase (61),
Akt (12), calcium/calmodulin-dependent protein kinase II
(58), and calcium/calmodulin-dependent protein kinase IV
(37).
PKCs are a family of serine/threonine kinases that assume
important physiological functions and are highly activated in
certain malignancies (19). They can be categorized into three
subfamilies, conventional, novel, and atypical, based on the
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structural domains that confer their coactivator dependency
(41). A novel isoform, PKC, has been shown to play an im-
portant role in mucin exocytosis stimulated by human neutro-
phil elastase (45) and mucin gene expression induced by phor-
bol 12-myristate 13-acetate (62). Conventional PKC (cPKC)
isoforms were shown to be directly activated by RA (48). A
recent crystallography study showed that RA may exert its
effect by binding to the C2 domain of PKC, a structure domain
that present only in conventional isoforms (43). However, as
PKCs are differentially expressed in different cell types (19), it
is not known which isoform of cPKC is involved in RA-induced
CREB activation and whether such an activation has a role in
mucin gene expression and the normal differentiation of lung
epithelial cells. Here, we hypothesized that RA-induced CREB
activation has a critical role in mucin gene (especially
MUC5AC) regulation and triggers early events in the differen-
tiation of the bronchial epithelia. To test our hypothesis, we
performed the study described herein to further determine the
role of molecules involved in the nonclassical signaling path-
way of RA in the activation of CREB. In addition, we analyzed
the transcriptional action of CREB on the promoter region of
the MUC5AC gene in NHTBE cells. An exploration of tran-
scriptional regulation demonstrated that the RA-induced up-
regulation of the MUC5AC gene in NHTBE cells was mediated
by the CRE motif on the promoter. RA transactivates the
promoter function of the other secretory mucin genes, includ-
ing MUC2 and MUC5B, which are also regulated by CREB.
Together, these findings give new insight into the role of
CREB in mucin gene expression in mucous cell differentiation.
MATERIALS AND METHODS
Antibodies and reagents. Antibodies against MEK1/2, phospho-MEK1/2 (Ser-
217 and Ser-221 phosphorylated), Raf, phospho-Raf (Ser-259 phosphorylated),
extracellular signal-regulated kinase (ERK), phospho-ERK (Thr-202 and Thr-
204 phosphorylated), RSK, phospho-RSK (Ser-380 phosphorylated), and epider-
mal growth factor receptor were purchased from Cell Signaling Technology
(Beverly, MA). Antibodies against PKC, phospho-PKC (Ser-659 phosphory-
lated), PKCII, RAR, RAR, RAR, and RXR were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). An antibody against -actin (clone AC-
15) was purchased from Sigma-Aldrich (St. Louis, MO). Antibodies against
CREB, phospho-CREB (Ser-133 phosphorylated), phospho-PKCII (Thr-641
phosphorylated), and cPKC were purchased from Upstate Biotechnology
(Waltham, MA). MUC5AC antibody was purchased from NeoMarkers (Free-
mont, CA). All-trans RA, 9-cis RA, 13-cis RA, retinol, cycloheximide, and acti-
nomycin D were purchased from Sigma-Aldrich. A pan-RAR antagonist (Ro
61-8431) and a pan-RXR antagonist (Ro 26-5405) were provided by Roche
Bioscience (Palo Alto, CA). Other signal transduction inhibitors [H89, wortman-
nin, PP2, U0126, SB203580, Sp600125, staurosporine, Go6976, GF109203X,
rottlerin, U73122, 2,5-dideoxyadenosine, calphostin C, EGTA–ethyleneglycol-
bis(-aminoethyl)-N,N,N,N-tetraacetoxymethyl ester (EGTA-AM), 1,2-bis(o-
aminophenoxy)ethane-N,N,N,N-tetraacetic acid tetra(acetoxymethyl) ester
(BAPTA-AM), 12-O-tetradecanoyl-phorbol 13-acetate (TPA), and 8-bromo
(8Br)-cAMP] were purchased from Calbiochem (San Diego, CA). All of the
chemicals were dissolved in dimethyl sulfoxide (DMSO), and all other reagents
were of analytical reagent grade or better.
NHTBE cell culture. NHTBE cells were purchased from Clonetics (San Diego,
CA). Second-passage NHTBE cells (1  105) were seeded onto a 24-mm Trans-
well plate (Corning, Acton, MA) and grown in serum-free growth factor-supple-
mented and hormone-supplemented culture medium as described previously (1,
18, 30, 32). After 7 days under immersed culture conditions, the cell culture was
switched to an air-liquid interface system. For signal transduction experiments,
NHTBE cells were incubated with bronchial epithelial cell basal medium for 24 h
prior to RA treatment. To study the effect of chemical inhibitors on signal
transduction pathways, cells were pretreated with each inhibitor 2 h prior to
treatment with RA. To study the effect of RA on MUC5AC mRNA expression
and secretion, NHTBE cells were grown in RA-deficient medium for 7 days and
then further incubated with 1 M RA for the indicated times or with various
concentrations of RA for 24 h. All cells were grown at 37°C in a humidified
atmosphere of 5% CO2.
QRT-PCR analysis. Total RNA was extracted from NHTBE cells and the
NCI-H292 (H292) lung cancer cell line using RNeasy Mini kits (QIAGEN,
Valencia, CA). Each reverse transcription (RT) reaction was performed using 1
g of total RNA that was reverse transcribed into cDNA using random hexamer
primers (GeneAmp RNA PCR core kit; Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions. PCR conditions were an initial
reaction at 95°C for 5 min followed by 30 cycles at 95°C, 55°C, and 72°C for 30 s
each. PCR analysis of -actin expression (Ambion, Austin, TX) was performed
as an internal control. The primer sequences, which were described previously
(24), were as follows: 5-AGCCTACGTGCCAAAAAAGG-3 (PKC forward),
5-TCTAGGTGTGGAGGCAAATGG-3 (PKC reverse), 5-ACCATGGAAT
CTGGAGCCGAGAAC-3 (PKCI forward), 5-CTGTAGGAAGGCCTCCTT
GAAAGA-3 (PKCI reverse), 5-ACCATGGAATCTGGAGCCGAGAAC-3
(PKCII forward), 5-CTGTAGGAAGGCCTCCTTGAAAGA-3 (PKCII re-
verse), 5-ACCATGGAATCTGGAGCCGAGAAC-3 (PKC forward), 5-CTG
TAGGAAGGCCTCCTTGAAAGA-3 (PKC reverse), 5-AGCCTACGTGCC
AAAAAAGG-3 (RAR forward), 5-TCTAGGTGTGGAGGCAAATGG-3
(RAR reverse), 5-ACCATGGAATCTGGAGCCGAGAAC-3 (CREB for-
ward), and 5-CTGTAGGAAGGCCTCCTTGAAAGA-3 (CREB reverse). PCR
products were then separated in a 2% agarose DNA gel and stained with ethidium
bromide. To investigate the expression level of MUC5AC, mRNA expression was
determined using quantitative RT-PCR (QRT-PCR). MUC5AC primer sequences
were as follows: 5-TGTGGCGGGAAAGACAGC-3 (forward) and 5-CCTTCC
TATGGCTTAGCTTCAGC-3 (reverse). MUC5B primer sequences were as fol-
lows: 5-CGATCCCAACAGTGCCTTCT-3 (forward) and 5-CCTCGCTCCGCT
CACAGT-3 (reverse). MUC2 primer sequences were as follows: 5-GCTGGCTG
GATTCTGGAAAA-3 (forward) and 5-TGGCTCTGCAAGAGATGTTAGC-3
(reverse). Human GAPDH (glyceraldehyde-3-phosphate dehydrogenase) endoge-
nous control reagents (Applied Biosystems) were used as normal controls. The PCR
was performed in a 96-well format using the iCycler Real Time PCR detection
system (Bio-Rad, Richmond, CA) by using SYBR green PCR core reagent (Applied
Biosystems). Samples were analyzed in triplicate in a PCR program with an initial
3-min 95°C step followed by 40 cycles of 1 min at 95°C and 1 min at 65°C. After each
analysis, a melting curve was performed to ensure that no primer dimers or second-
ary products were formed, and data were then analyzed using the accompanying
iCycler version 3.1 software (Bio-Rad).
PKC activation assay and preparation of cell fractionation. To investigate
PKC activation in NHTBE cells, we measured the translocation of PKC and
PKCII from cytosolic to membrane fractions as described previously (14).
Briefly, the cells were treated with 1 M RA for the indicated time periods at
37°C and then washed twice with ice-cold phosphate-buffered saline (PBS),
scraped, and lysed using Tris-sucrose buffer (10 mM Tris-HCl [pH 7.5], 0.25 M
sucrose, 0.2 mM CaCl2, 1 mM EDTA) supplemented with protease inhibitor
cocktail tablets (Roche Diagnostics, Indianapolis, IN). The cells were sonicated
using a sonic dismembrator (Fisher Scientific, Pittsburgh, PA) three times for
30 s each with 5 min of incubation on ice between sonications. Nuclei and
unbroken cells were removed by centrifugation at 1,000  g for 10 min in a
Beckman SW28 rotor (Beckman Coulter, Fullerton, CA) at 4°C. The resulting
supernatant was further centrifuged at 100,000  g for 60 min in a Beckman
SW28 rotor at 4°C. The supernatant from this centrifugation (cytosolic fraction)
was removed and saved. The pellet (membrane fraction) was resuspended in
Tris-sucrose buffer containing 1% Triton X-100 and 10 mM 2-mercaptoethanol.
The suspensions were then briefly sonicated and centrifuged (100,000  g for 60
min at 4°C). Insoluble material was discarded, and the supernatant was collected
as a Triton X-100-soluble membrane fraction after the last centrifugation. The
protein concentrations of the cytosolic and nuclear fractions were determined
according to the Bradford protocol (4).
Western blot analysis. Western blot analysis was performed as previously
described (1). Briefly, whole-cell extracts were prepared using 2 sodium dode-
cyl sulfate (SDS) Laemmli lysis buffer. Equal amounts of total protein (20 g)
were resolved by 10% SDS-polyacrylamide gel electrophoresis. Proteins that
were reactive with primary antibody were visualized with a horseradish peroxi-
dase-conjugated secondary antibody and enhanced chemiluminescence reagents
(Amersham Bioscience, Arlington Heights, IL). Equal protein loading was con-
firmed by stripping the blots and reprobing them with an anti--actin antibody.
RNA interference. RNA interference was performed with NHTBE cells by
using the siIMPORTER small interfering RNA (siRNA) transfection reagent
(Upstate Biotechnology) as described previously (1). For target gene silencing,
SMARTpool-sequenced siRNAs targeting human PKC (GenBank accession
no. NM_002953), RSK1 (GenBank accession no. NM_002953), RSK2 (GenBank
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accession no. NM_004586), ERK2 (GenBank accession no. NM_002745), RAR
(GenBank accession no. NM_000964), RAR (GenBank accession no.
NM_000965), RAR (GenBank accession no. NM_000966), RXR (GenBank
accession no. NM_002957), or CREB (GenBank accession no. NM_004379) and
a nonspecific control pool (siRNA-negative control; Dharmacon RNA Technol-
ogies, Lafayette, CO) were diluted and stored according to the manufacturer’s
instructions. NHTBE cells at 60% or 70% confluence were transfected with a
final concentration of 100 nM SMARTpool siRNA or the nonspecific control
pool. Cells were analyzed 72 h after transfection.
Transient transfection and luciferase assays. Transfections of NHTBE cells
were performed as described previously (1). Briefly, NHTBE cells (1  104
cells/well) were plated in 12-well plates using bronchial epithelial growth medium
in the absence of RA. When the cells reached 60% to 70% confluence, trans-
fections were performed using Lipofectamine 2000 transfection reagent (Invitro-
gen, Carlsbad, CA) with the CRE promoter-luciferase reporter plasmid
(Stratagene, La Jolla, CA), the construct of deletion mutants of MUC5AC or
point-mutated CRE sites of MUC5AC, and the -galactosidase (-gal) reporter
construct (BD Biosciences Clontech, Palo Alto, CA) according to the manufac-
turer’s instructions. Four hours after transfection, cells were treated with RA and
cultured for another 48 h. The luciferase activity was measured using a Lumat LB
9507 luminometer (EG&G, Berthold, Germany). -gal activity was measured
using a -gal enzyme assay system (Promega, Madison, WI) and used to nor-
malize transfection efficiency.
For knockdown by siRNA, 100 nM siRNA of the indicated target gene or
nonspecific siRNA was cotransfected with luciferase plasmid and -gal reporter
constructs. The cells were treated with or without RA for another 24 h after 72 h
of transfection, when target protein levels had been reduced by 70% to 80% as
assessed by Western blot analysis. After transfection, whole-cell lysate was pre-
pared for luciferase assay.
Immunofluorescence analysis. For immunofluorescence staining, NHTBE
cells were grown on coverslips for 7 days in an RA-deficient medium. After
treatment with RA, the cells were fixed in a methanol-acetone mixture (1:1,
vol/vol), washed with PBS, and blocked with 5% preimmune serum for 30 min.
The cells were then incubated with the indicated primary antibodies (1:100
dilution) for 2 h at room temperature. The coverslips were washed with PBS
containing 0.1% Tween 20, incubated with an AlexaFluor 488-tagged secondary
antibody (Molecular Probes, Eugene, OR) for 1 h at room temperature, and then
counterstained for nuclei with 4,6-diamidino-2-phenylindole (DAPI) for 30 min.
After being washed with PBS, slides were mounted using the SlowFade Antifade
kit (Molecular Probes). The stained cells were visualized under a fluorescence
microscope (Axioskop 40; Carl Zeiss, Thornwood, NY), and the images were
captured at a magnification of 400 and stored using the AxioVision software
program (Carl Zeiss) according to the instructions provided by the manufacturer.
Quantification of secreted MUC5AC. To analyze the production of MUC5AC,
accumulating apical secretion fluid with or without RA was collected and ana-
lyzed by dot blot analysis (16). Briefly, diluted apical secretion fluid was applied
to nitrocellulose membranes, which were incubated with human MUC5AC an-
tibody, followed by a reaction with horseradish peroxidase-conjugated goat anti-
mouse immunoglobulin G (IgG). The signal was detected by chemiluminescence
using the ECL kit (Amersham, Little Chalfont, Buckinghamshire, United King-
dom). The blot intensities were analyzed densitometrically using Quantity One
4.6.1 software (Bio-Rad).
Preparation of MUC5AC promoter-luciferase constructs. Methods to measure
MUC5AC promoter activity with luciferase as a reporter were reported previ-
ously (17). Fragments ranging in size from 3.7 kb (nt 	3752 to 7) to 0.29 kb (nt
	296 to 7), which were located immediately adjacent to the 5 transcriptional
start site of human MUC5AC, were generated by digestion with exonuclease
(Erase a Base system; Promega Corp., Madison, WI) of the 3.7-kb fragment of
the MUC5AC promoter and cloned into the pGL3-Basic luciferase vector (Pro-
mega Corp.).
Site-directed mutations of the human MUC5AC promoter were made in the
context of MUC5AC-LUC (positions 	1366 to 7), using the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA) and confirmed by se-
quencing. The oligomers used to introduce point mutations included the follow-
ing: M1 (5-CCATCAAGACTCTTGAACTGGCCC-3), M2 (5-CCATCAAGT
GGTGTGAACTGGCCC-3), and M3 (5-CCATCAAGTGACTGACACTGGC
CC-3) (mutations are shown in boldface type; underlined type indicates putative
CRE sites) (56).
EMSA. To assess the DNA-binding activity of CREB, we performed an elec-
trophoretic mobility shift analysis (EMSA) as described previously (1), with
necessary modifications. Briefly, nuclear proteins from RA-treated or untreated
cells were prepared and stored at 	80°C. For EMSA, oligonucleotides corre-
sponding to the consensus CRE sequences (5-AGAGATTGCCTGACGTCAG
AGAGCTAG-3 [boldface type indicates CRE {Santa Cruz Biotechnology}]),
CRE-specific sequences in the MUC5AC promoter region at nt 	878 to 	871
(wild type [wt] [5-CCATCAAGTGACTTGAACTGGCCC-3 {boldface type in-
dicates putative CRE}]), and the CRE mutant sequence (M1 [5-CCATCAAG
ACTCTTGAACTGGCCC-3], M2 [5-CCATCAAGTGGTGTGAACTGGCCC-
3], and M3 [5-CCATCAAGTGACTGACACTGGCCC-3 [underlining indicates
a CRE mutant]) were synthesized, annealed, and end labeled with [-32P]ATP using
T4 polynucleotide kinase. Nuclear extract (10 g) was incubated at room tempera-
ture for 30 min with the 32P-labeled CRE probe in binding buffer [20% glycerol, 5
mM MgCl2, 2.5 mM EDTA, 2.5 mM dithiothreitol, 250 mM NaCl, 50 mM Tris-HCl
(pH 7.5), and 0.25 mg/ml poly(dI-dC)]. For supershift analysis, nuclear extracts were
incubated with antibodies against phospho-CREB (pCREB) or CREB and wild-
type CRE-oligonucleotide probe for 30 min at 37°C, and the complex was then
analyzed by EMSA. Antibodies against preimmune serum were included as negative
controls. The DNA-protein complexes were resolved by electrophoresis in 5% non-
denaturing polyacrylamide gels in 0.5 TBE (1 TBE is 25 mM Tris base, 25 mM
boric acid, and 0.5 mM EDTA). Gels were dried and autoradiographed at 	80°C.
For EMSA, all studies were repeated three times; consistent results were obtained.
ChIP assay. To determine transcription factor binding on the promoter re-
gion, we performed chromatin immunoprecipitation (ChIP) assays (34). NHTBE
cells were treated with RA for 4 h, cross-linked with 1% formaldehyde for 10 min
at 37°C, and then washed with cold PBS. The cell pellet was resuspended in 0.3
ml of lysis buffer (1% SDS, 100 mM NaCl, 50 mM Tris-HCl [pH 8.1], 5 mM
EDTA), followed by sonication to an average DNA length of 500 to 1,000 bp,
and then rotated at 4°C overnight. After interaction with protein A beads and
incubation overnight at 65°C to reverse the cross-links, the DNA was dissolved in
Tris-EDTA buffer and then analyzed by PCR. The antibodies anti-CREB, anti-
phospho-CREB (Upstate Biotechnology), and normal rabbit IgG were added
separately into the reaction solutions. Primers used for PCR were from
MUC5AC promoter sequences 5-TCACTGGGACCTTTCTGTGCT-3 (for-
ward) and 5-ACTGAAGTAGCGCCAGCCA-3 (reverse).
Data analysis. For all transfection assays and QRT-PCR analyses, values are
given as means 
 standard errors (SE) of triplicate assays in three independent
experiments. Statistical analysis was performed with the Prism program (Graph-
Pad Software, San Diego, CA) using one-way analysis of variance, followed by
Dunnett’s test for comparing experiment groups against a single control or by
Bonferroni’s test for paired comparison.
RESULTS
PKC is a predominant cPKC isozyme expressed in
NHTBE cells. We previously showed that RA induced CREB
activation via PKC in NHTBE cells (1). A recent crystallogra-
phy study indicates that RA activates PKC by binding to its
C2 domain (43). Because this domain is present only in cPKC,
to further determine which cPKC isotype mediates the RA
activation of CREB, we measured the level of expression of
cPKC isozymes in NHTBE cells using RT-PCR and Western
blot analysis with isoform-specific primers and antibodies.
H292 cells were included as a control for their known high
expression level of PKC. As shown in Fig. 1, PKC was highly
expressed in NHTBE and H292 cells. However, PKCI and
PKCII were barely detectable in NHTBE cells although fairly
detectable in H292 cells. PKC was not detected in either cell
type (Fig. 1A). We further confirmed the predominant expres-
sion of PKC among cPKC isoforms in NHTBE cells using
Western blot analysis with antibodies against PKC, PKC/
/, and PKCII (Fig. 1B). We used an antibody that recog-
nizes all three types (//) to assess the level of PKCI
because a PKCI-specific antibody was not available. Immu-
noblotting of PKC was not performed because we did not
detect mRNA of PKC in RT-PCR. This result is in agreement
with data reported previously by Park et al. (45) showing that
NHTBE cells express PKC, PKC, PKC, and PKC but not
PKC, PKC, or PKCε. These results clearly showed that
PKC is a major cPKC isozyme expressed in NHTBE cells.
VOL. 27, 2007 CREB REGULATES MUCIN GENE EXPRESSION 6935
RA activates PKC and CREB, and activated PKC trans-
locates from the cytoplasm to plasma and perinuclear mem-
branes. We next determined the effect of RA on the activation
status of PKC. We analyzed the effect of RA on PKC phos-
phorylation at Ser-659, which indicates activation of PKC (3,
44), and PKC translocation using Western blot and immuno-
fluorescence analysis. RA clearly induced phosphorylation of
PKC and CREB in a time-dependent manner (Fig. 2A). We
detected PKC phosphorylation as early as 5 min after treat-
ment with RA; the level of phosphorylation reached a maxi-
mum at 120 min. CREB phosphorylation showed a similar
pattern. The levels of expression of PKC and CREB re-
mained unchanged. We also observed the occurrence of RA-
induced phosphorylation of PKC and CREB in a dose-de-
pendent manner (Fig. 2B). Both PKC and CREB were
phosphorylated with treatment with as little as 10 nM RA for
30 min.
To determine whether RA relocates PKC in bronchial ep-
ithelial cells, we isolated nuclear, cytoplasmic, and membrane
fractions from the NHTBE cells treated with 1 M RA for 15,
30, or 60 min. As shown in Fig. 2C, the majority of PKCs were
located in the cytoplasm of RA-deficient NHTBE cells. How-
ever, upon treatment with RA, more than 80% of the PKCs
were detected in the membrane and nuclear fractions within 15
min after treatment, demonstrating translocation of PKC by
RA. As analyzed using Western blot analysis to detect phos-
phorylated PKC, PKC translocated to nuclear and mem-
brane fractions in a phosphorylated form. In contrast, PKC
residing in the cytoplasm was not phosphorylated. Treatment
with RA did not cause the translocation of cytoplasmic
PKCII. These results are consistent with those of immuno-
cytochemical analyses showing that most of the diffusely local-
ized PKC in the cytoplasm when the cells were in an RA-
deficient state was translocated to the plasma and perinuclear
membranes within 15 min after treatment with RA (Fig. 2D).
Consistent with our previous results, the majority of CREB
was localized in nuclear fractions. Phosphorylation of CREB
FIG. 1. PKC is highly expressed in NHTBE and H292 cells. NHTBE
cells were cultured for 7 days in RA-deficient medium. (A) RT-PCR
products amplified using specific primers for the cPKC isotypes from total
RNA. The RT-PCR products were visualized on a 2% agarose gel con-
taining 0.01% (wt/vol) ethidium bromide. (B) Equal amounts of whole-
cell lysates were prepared and subjected to Western blot analysis with
antibodies against PKC, PKC, and PKCII. -Actin expression was
used as an internal control for RT-PCR and Western blotting. Both
figures are representative of three independent experiments.
FIG. 2. Time- and dose-dependent activation of PKC and CREB
by RA. NHTBE cells grown in an RA-deficient medium were treated
with 1 M RA for the indicated periods (A) or RA at the indicated
concentrations for 30 min (B). (C) RA-induced PKC activation was
determined according to the translocation of PKC. RA-treated
NHTBE cells were fractionated to nuclear (N), cytosolic (C), and
membrane (M) fractions for the indicated periods as described in
Materials and Methods. Equal loading of proteins in each compart-
ment was verified using Western blot analysis with the indicated anti-
bodies. EGFR, EGF receptor. (D) NHTBE cells grown on an RA-
deficient medium on coverslips for 7 days were subjected to
immunocytofluorescence analysis. NHTBE cells were incubated with a
vehicle (Cont) (top) or 1 M RA (bottom) for 15 min before fixation
and stained with a mouse monoclonal anti-PKC antibody followed by
anti-mouse AlexaFluor 488 antibodies (green). Nuclei were stained
with DAPI (blue), and the two images were then merged. All figures
are representative of three independent experiments.
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was maximal after 15 min of treatment with RA and continued
for another 60 min with no change in the level of CREB
expression in nuclear fractions (1).
Activation of PKC and CREB by RA is independent of
RAR and RXR. To determine whether RAR and RXR are
involved in the activation of PKC by RA, we initially exam-
ined the effect of several retinoids, including 9-cis RA, 13-cis
RA, and retinol, on the phosphorylation of PKC and CREB
in NHTBE cells. We found that all these retinoids equipotently
induced the phosphorylation of PKC and CREB (Fig. 3A).
Furthermore, all-trans RA, 9-cis RA, 13-cis RA, and retinol
induced the transactivation of the CRE-luciferase reporter
four- to fivefold, which is similar to the capacity of TPA and
8Br-cAMP, which were used as positive controls for CRE
activation (Fig. 3B). These findings clearly demonstrate that
all-trans RA is not the only retinoid that activates PKC and
CREB.
To determine whether RAR and RXR are required for the
activation of PKC by RA, we next examined the effects of
pan-RAR and pan-RXR antagonists on the activation of PKC.
We incubated NHTBE cells with 10 M Ro 61-8431 and Ro
26-5405 before treatment with RA. Pretreatment with either
antagonist did not block RA-induced activation of PKC or
CREB (Fig. 4A). As we previously reported (1), these antag-
onists did not affect the RA-induced CRE transactivation
either.
To further rule out the involvement of RAR and RXR in
this rapid activation of PKC by RA, we silenced the expres-
sion of RAR, RAR, RAR, and RXR using siRNA; we
silenced only the  type of RXR because it is known to be a
predominant RXR isotype in eliciting the classical action of
RA. At 72 h after transfection of siRNAs targeting RARs and
RXR, we confirmed the maximal silencing of target gene
expression (data not shown). Western blot analysis of RA-
induced active PKC levels after transfection with pooled syn-
thetic siRNAs for RARs and RXR revealed that the deple-
tion of RARs and RXR in NHTBE cells did not affect
RA-induced rapid phosphorylation of either PKC or CREB
(Fig. 4B). Silencing of RARs, RXR, and a nonspecific control
pool (negative control for siRNA) did not affect the activation
status of PKC or CREB in the vehicle-treated control. We
also examined the effect of RARs and RXR knockdown on
CRE-luciferase activity and found no effect of such a knock-
FIG. 3. Activation of PKC and CREB by retinoids and retinol. (A) NHTBE cells were treated with 1 M 9-cis RA, 13-cis RA, or retinol for
the indicated periods. After the treatment, equal amounts of whole-cell lysates were prepared and subjected to Western blot analysis using the
indicated antibodies. (B) NHTBE cells were transiently transfected with a CRE promoter-driven luciferase-containing vector. After transfection,
cells were further incubated with RA, 9-cis RA, 13-cis RA, or retinol for 48 h. TPA and 8Br-cAMP were used as positive controls. Cell lysates were
then assayed for luciferase activity. The data represent luciferase units normalized according to -gal in the same cell lysates. Values are the
means 
 SE of triplicate experiments, and the figures represent three independent experiments.
FIG. 4. RAR/RXR-independent activation of PKC by RA. RA-
induced PKC activation does not involve classical retinoid receptors.
(A) To examine the role of RAR and RXR in RA-induced PKC
activation, NHTBE cells were preincubated with 10 M Ro 61-8431
and Ro 26-5405 for 2 h and further incubated with or without RA for
30 min. Equal amounts of whole-cell lysates were subjected to Western
blot analysis. Cont, control. (B) NHTBE cells were transfected with
siRNA of RAR, RAR, RAR, and RXR combined (RAR/
RXR-siRNA) or a nonspecific control pool (NS-siRNA) as described
in Materials and Methods. Control cells were not transfected. Three
days after transfection, the cells were treated with or without RA for
30 min. After the treatment, equal amounts of whole-cell lysates were
prepared and subjected to Western blot analysis. All figures are rep-
resentative of three independent experiments.
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down on the RA-induced CRE transcriptional activity (data
not shown). Taken together, these results confirmed that the
RA-induced rapid activation of PKC and CREB does not
require RAR or RXR function in NHTBE cells.
cPKC and ERK are critically involved in RA-induced acti-
vation of CREB. To investigate the signaling pathway by which
RA induces the activation of PKC and CREB, we treated
NHTBE cells with various signaling inhibitors alone or in com-
bination with RA and determined the activation status of
PKC and CREB. We found that of the signal transduction
inhibitors used, only staurosporine (general PKC inhibitor),
Go6976 (cPKC inhibitor), and GF109203X (cPKC and novel
PKC inhibitor) substantially blocked PKC and CREB activa-
tion induced by RA (Fig. 5A). Other inhibitors, including H89
(PKA inhibitor), wortmannin (phosphoinositide 3-kinase in-
hibitor), PP2 (Src tyrosine kinase inhibitor), SB203580 (p38
MAPK inhibitor), Sp600125 (c-Jun N-terminal kinase inhibi-
tor), and rottlerin (novel PKC inhibitor), did not block RA
activation of PKC or CREB. Also, U0126 (MEK1/2 inhibitor)
did not inhibit the RA activation of PKC but did inhibit the
activation of CREB. These results reconfirmed that cPKC iso-
types and ERK1/2 are involved in the RA activation of CREB.
To determine whether the adenylate cyclase (AC)-cAMP-
PKA pathway is involved in the RA activation of PKC and
CREB, we inhibited endogenous AC using the AC inhibitor
2,5-dideoxyadenosine in NHTBE cells before treatment with
RA. As shown in Fig. 5B, 2,5-dideoxyadenosine did not in-
hibit the RA-induced activation of PKC or CREB. We also
sought to determine whether phospholipase C (PLC) is in-
volved in the RA activation of PKC and CREB by treating
NHTBE cells with U73122 (an inhibitor of PLC) before treat-
ment with RA. Treatment with 10 M U73122 did not affect
the activation of PKC or CREB (Fig. 5B).
To further determine whether diacylglycerol and Ca2 are
required for RA-induced PKC and CREB activation, we
treated NHTBE cells with the indicated concentrations of cal-
phostin C (diacylglycerol inhibitor), EGTA-AM, or BAPTA-AM
(an intracellular Ca2 chelator) before treatment with RA. As
shown in Fig. 5B, treatment with calphostin C did not block
RA-induced activation. However, treatment with inhibitors
FIG. 5. RA induces CREB activation via the PKC/MEK/ERK pathway but not PKA or other MAPKs or tyrosine kinase pathways.
(A) NHTBE cells were preincubated with various signal transduction inhibitors (10 M) for 2 h and then further treated with or without 1 M
RA for 30 min. Cont, control; Wort, wortmannin; SB, SB203580; SP, SP600125; Sta, staurosporine; Go, Go6976; GFX, GF109203X; Rot, rottlerin.
(B) NHTBE cells were preincubated with the PLC inhibitor U73122, the AC inhibitor 2,5-dideoxyadenosine (25-dd-Ado), or the PKC inhibitor
calphostin C at the indicated concentrations for 2 h before treatment with RA. (C) NHTBE cells were incubated with membrane-permeable
specific calcium chelators (20 M EGTA-AM or 50 M BAPTA-AM) for 2 h before treatment with RA. Cells treated as controls received
equivalent amounts of solvent (DMSO) (Cont). Whole-cell lysates were prepared, and equal amounts of proteins were subjected to Western blot
analysis using the indicated antibodies. All figures are representative of three independent experiments.
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that specifically chelated intracellular calcium did not inhibit
the phosphorylation of PKC but slightly blocked the phos-
phorylation of CREB (Fig. 5C).
RA activation of CREB is mediated by the PKC/Raf/MEK/
ERK/RSK signaling pathway. To determine whether RA-ac-
tivated PKC uses the linear signal transduction of the Raf/
MEK/ERK/RSK signaling pathway for CREB activation, we
examined the effect of RA on the PKC/Raf/MEK/ERK/RSK/
CREB signaling pathway after the knockdown of the expres-
sion of PKC with an siRNA targeting PKC. We verified the
successful knockdown of PKC expression in NHTBE cells
using Western blot and RT-PCR analyses (Fig. 6A). Treat-
ment with RA resulted in the activation of the PKC/Raf/
MEK/ERK/RSK/CREB signaling cascade in control transfec-
tions with a nonspecific siRNA. However, RA activation of this
signaling pathway was completely blocked in PKC-silenced
NHTBE cells (Fig. 6A). This result clearly demonstrated that
PKC is indispensable for RA activation of the CREB signal-
ing cascade.
We further examined the roles of ERK and RSK in the RA
FIG. 6. RA-induced PKC-CREB activation is mediated by the Raf/MEK/ERK/RSK signaling pathways. NHTBE cells were transfected with
PKC-siRNA (A), ERK-siRNA (B, left), RSK-siRNA (B, right), or a nonspecific control pool (NS-siRNA) as described in Materials and Methods. Three
days after transfection, the cells were further treated with or without RA for 30 min. After the treatment, equal amounts of whole-cell lysates were
prepared and subjected to Western blot analysis using the indicated antibodies. All figures are representative of three independent experiments. -Actin
expression was used as an internal control. NT, nontransfection. (C) To determine the effects of siRNA on CRE transactivation, cells were cotransfected
with a CRE-luciferase vector and siRNA of PKC, ERK, RSK, or CREB. After transfection, cells were incubated with or without RA for 48 h. Cell
lysates were then assayed for luciferase activity. The data represent luciferase units normalized according to -gal in the same cell lysates. Values are
means 
 SE of triplicate experiments, and the figures are representative of three independent experiments.
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activation of CREB signaling using a knockdown approach.
We transfected NHTBE cells with small interfering ERK1/2
(siERK1/2) or small interfering RSK1/2 and treated them with
RA for 3 days after transfection. Compared with the control,
transfection of NHTBE cells with siERK1/2 dramatically
blocked ERK, RSK, and CREB activation, whereas the acti-
vation of PKC (which is upstream of ERK) remained intact
(Fig. 6B, left). The knockdown of RSK1/2 blocked the activa-
tion of CREB (downstream of RSK) only, without affecting
upstream PKC or ERK (Fig. 6B, right). To determine
whether the inhibition of this signaling cascade inhibits the
transcriptional activity of CREB, we transfected NHTBE cells
with a CRE-luciferase reporter vector alone or with small
interfering PKC, siERK1/2, or small interfering CREB
(siCREB). As shown in Fig. 6C, the knockdown of individual
signaling mediators significantly blocked the RA-induced tran-
scriptional activity of CREB.
ERK and RSK are activated by RA, and RSK but not ERK
is translocated to the nucleus. To determine which molecule
enters the nucleus upon stimulation with RA, we examined the
localization of activated RSK and ERK in NHTBE cells using
Western blot analysis and immunocytofluorescence analysis.
As shown in Fig. 7A, the majority of RSKs and ERKs were
located in cytoplasmic fractions in the absence of RA. Treat-
ment with RA (1 M for 30 min) reduced the amount of RSK
in the cytoplasm while increasing the amount of RSK in the
nuclear fractions. We detected phosphorylated RSKs only in
the nuclear fractions. However, we detected ERK only in the
cytoplasmic fractions, and treatment with RA induced only the
activation of ERK but not the translocation of it.
To further examine the location of RSK and ERK in
NHTBE cells, we performed immunocytochemical fluores-
cence analysis of these cells. As shown in Fig. 7B, unphosphor-
ylated RSK resided in the cytoplasm, and treatment with RA
induced the relocalization of RSK to the nuclei. We detected
phosphorylated RSK only in the nuclei of RA-treated NHTBE
cells. Also, the cPKC inhibitor Go6976 completely blocked the
RA-induced activation and translocation of RSK. In contrast,
RA phosphorylated ERK, but ERK was not translocated into
the nuclei, although RA-induced phosphorylated ERK showed
a tendency to migrate to the perinuclear membrane (Fig. 7C).
The cPKC inhibitor Go6976 completely blocked the activation
of ERK as expected. These results clearly demonstrated the
translocation of active RSK but not ERK from the cytoplasm
to the nucleus. Consistently, CREB resided in nuclear fractions
in the absence of RA, and RA induced the phosphorylation of
nuclear CREB (Fig. 7D). Again, the cPKC inhibitor Go6976
completely abolished the phosphorylation of CREB.
Mapping of RA-induced transactivation regions within the
MUC5AC promoter. To determine whether RA induces the
upregulation of MUC5AC, we treated the NHTBE cells with 1
M RA for different periods of time or with different concen-
trations of RA for 24 h and measured MUC5AC gene expres-
sion and secretion. We found that RA increased both the
MUC5AC mRNA level and protein secretion in a time- and
dose-dependent manner (Fig. 8).
Next, to determine the promoter regions of the MUC5AC
gene responsible for the RA-induced transcriptional activity,
luciferase reporter vectors with progressive 5 deletion mutants
of the MUC5AC promoter were constructed and analyzed in
NHTBE cells (Fig. 9A). Results of the transient transfection
study showed that RA increased the luciferase activity of the
construct with the region from nt 	3752 to 7 of the
MUC5AC promoter. Deletion of the MUC5AC 5-flanking se-
quence from nt 	3752 to 	1039 had no apparent effect on the
promoter activity induced by RA. However, this activation was
completely abolished when the deletion proceeded from nt
	1039 to 	596. This result suggests that the region from nt
	1039 to 	596 is the core promoter of MUC5AC that re-
sponds to RA and that positive regulatory elements might
locate between nt 	1039 and 	596. By comparing this core
promoter sequence with the TFsearch database (http://mbs
.cbrc.jp/research/db/TFSEARCH.html) (22), we found the pu-
tative CRE at nt 	878 using a threshold score of 78.0. The
native sequence of the putative CRE site in the sense strand is
5-TGACTTGA-3. To determine whether this cis-acting ele-
ment is critical for RA-induced MUC5AC regulation, we mu-
tated the putative CREB binding site by site-directed mutagen-
esis (Fig. 9B). Results of the transient transfection study
indicated that mutant constructs (M1, M2, and M3) abolished
the RA responsiveness of the wt MUC5AC promoter construct.
These results strongly suggested that the CRE motif located
between nt 	878 and 	871 on the MUC5AC promoter was
critical for the up-regulation by RA.
RA induced the binding of CREB to the CRE motif on the
MUC5AC promoter both in vitro and in vivo. Because pro-
moter analysis experiments showed that the CRE element was
involved in RA-induced MUC5AC gene transcription, we exam-
ined the RA-induced CREB-CRE interaction in vitro using
EMSA. We found that the binding of the radiolabeled MUC5AC
CRE oligonucleotides (wtCRE) to nuclear protein was in-
creased by RA treatment (Fig. 10A). The wtCRE band was
abolished by a 100-fold excess of cold wtCRE (Fig. 10A, lane
8). However, unlabeled CRE mutants (cold M1, M2, and M3)
(Fig. 10A, lanes 9 to 11) had no effect, indicating that the
binding is specific. To further confirm the binding of CREB to
the putative CRE motif after RA treatment, supershift assays
were performed with anti-CREB or anti-pCREB antibodies
(Fig. 10A, lanes 13 and 14). After incubation with either of
these antibodies, a further retention of the labeled wtCRE
band was observed (Fig. 10A, lanes 13 and 14). However,
normal rabbit IgG did not cause such a retention (Fig. 10A,
lane 12). These results indicated that CREB was the compo-
nent that binds to the putative CRE site in response to RA
stimulation. To confirm the interactions of CREB with puta-
tive CRE elements in vivo, a ChIP assay was performed using
anti-CREB and anti-pCREB antibodies (Fig. 10B). ChIP anal-
ysis showed that a single PCR band (273 bp), which represents
a fragment of the MUC5AC promoter, was detected in pre-
immunoprecipitation chromatin from both RA-treated and
untreated NHTBE cells. Such a PCR signal was observed only
in RA-treated NHTBE cells when immunoprecipitation was
performed with anti-pCREB antibody, but no PCR signal was
observed in controls with normal rabbit serum. Interestingly, in
vivo bindings of pCREB to this fragment occurred as early as
30 min (data not shown) and were sustained until 4 h after RA
treatment. Taken together, these results suggest that the bind-
ing of CREB to the CRE motif is critical for the RA-induced
transactivation of MUC5AC.
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FIG. 7. ERK and RSK are activated by RA, and RSK but not ERK is translocated to the nucleus. (A) NHTBE cells were preincubated with
10 M Go6976 (selective PKC inhibitor) for 2 h and then further treated with or without 1 M RA for 30 min. Nuclear (N) and cytosolic
(C) extracts were prepared as described in Materials and Methods. Equal amounts of proteins from each fraction were examined using Western
blot analysis with the indicated antibodies. (B to D) Immunocytofluorescence analysis of the activation and translocation of RSK, ERK, and CREB.
NHTBE cells grown in an RA-deficient medium on coverslips for 7 days were subjected to immunocytofluorescence analysis. Cells were
preincubated with or without 10 M Go6976 (Go) and then further incubated with a vehicle (Cont) (top) or 1 M RA (middle) for 30 min before
fixation. After fixation, the cells were stained with the indicated antibodies followed by anti-mouse AlexaFluor 488 antibodies (green). Nuclei were
stained with DAPI (blue) and then merged. All figures are representative of three independent experiments.
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Silencing of CREB decreases RA-induced mucin gene ex-
pression and secretion. To further assess the role of CREB in
RA-induced MUC5AC expression, we used the siRNA ap-
proach to silence CREB expression. As shown in Fig. 11A, RA
induced MUC5AC promoter activities in siRNA-untransfected
control and nonspecific siRNA-transfected samples by 5.8-fold
and 4.3-fold, respectively. However, such a promoter activity
was substantially reduced by an increasing concentration of the
CREB-siRNA transfection (10 nM siCREB, 3.9-fold; 50 nM
siCREB, 2.1-fold; 100 nM siCREB, 1.3-fold). 8Br-cAMP was
used as a positive control for CREB activation. To determine
the functional consequence of CREB silencing on MUC5AC
gene regulation, we then transiently transfected siCREB and
measured MUC5AC mRNA gene expression (Fig. 11B) and
secretion (Fig. 11C). RA induced the up-regulation of
MUC5AC mRNA expression and secretion. This up-regulation
was completely abolished when the cells were transfected with
siRNA of CREB (Fig. 11B and C). However, CREB knock-
down alone did not show any effect on the mRNA expression
level and secretion of MUC5AC compared with RA-untreated
control cells. The efficient CREB knockdown by siRNA was
verified by reduced CREB protein expression using Western
blot analysis (Fig. 11D). These results demonstrate a stimula-
tory effect of RA on MUC5AC gene transcription and also
indicated the critical role of CREB in MUC5AC transcriptional
regulation by RA.
Next, to determine whether CREB is required for the RA-
induced transactivation of MUC2 and MUC5B, we transiently
transfected various concentrations of siCREB and then measured
MUC2 and MUC5B gene expression. As shown in Fig. 11E and F,
RA induced MUC2 and MUC5B gene expression by 7.4-fold and
5.6-fold, respectively. However, increasing siCREB transfection
decreased RA-upregulated MUC2 and MUC5B expression in a
dose-dependent manner. The effective knockdown of CREB was
confirmed by CREB mRNA expression using RT-PCR analysis
(Fig. 11G). Taken together, these data strongly indicate that
CREB has an essential role in RA-regulated mucin expression
through CRE transactivation.
DISCUSSION
The major goals of our studies were to identify signaling
components involved in the activation of CREB by the non-
classical action of RA and to understand the role of CREB and
its signaling in the RA-induced regulation of mucin gene ex-
pression and mucous cell differentiation. In the present study,
we showed that RA, 9-cis RA, 13-cis RA, and retinol rapidly
activated the  isoform of cPKC in primary bronchial epithelial
cells and that RA-activated PKC transmitted the signal via
the Raf/MEK/ERK/RSK pathway to induce the transcriptional
activity of CREB. We further confirmed the critical role of
CREB in the RA-induced expression of mucin genes, including
MUC5AC, MUC5B, and MUC2.
Translocation of PKC from the cytoplasm to the membrane
is a key event in classical PKC activation (2, 39). We showed
that the majority of PKCs were rapidly phosphorylated and
translocated from the cytoplasm to the plasma and perinuclear
membranes after treatment with RA (Fig. 2D). A recent study
(13) showed that the calcium-binding loop and -strands 3 and
4 in the C2 domain of PKC are essential for the specific
translocation of PKC to the plasma membrane in response to
Ca2. Because the RA-binding site has been suggested to be
FIG. 8. RA induced MUC5AC mRNA expression and secretion. NHTBE cells were grown in RA-deficient medium for 7 days and then further
incubated with 1 M RA for the indicated times (A and C) or with the indicated concentrations of RA for 24 h (B and D). MUC5AC mRNA
expression and MUC5AC protein secretion were measured by QRT-PCR (A and B) and dot blot analysis (C and D) as described in Materials and
Methods. Values shown are means 
 SE of three independent experiments, each performed with triplicate cultures. , P  0.05; , P  0.01
(compared with RA-untreated control).
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the region of R239-V271 (48) that encompasses the third loop
of the calcium-binding loop, RA may act like Ca2 or enhance
the effect of Ca2 in coordinating the active structure of
PKC. In fact, our study showed that the deprivation of cyto-
solic Ca2 by a calcium chelator did not block the RA-induced
activation of PKC but slightly reduced downstream CREB
activation (Fig. 5C), indicating a cooperative effect between
Ca2 and RA, and that Ca2 may be needed for the full
activity of RA-activated PKC. Interestingly, unlike Ca2-in-
duced activation, which translocates PKC only to the inner
leaflet of the plasma membrane (13), RA stimulation induced
the translocation of PKC to both the plasma membrane and
the perinuclear membrane. It has been suggested that nucleus-
translocated PKC may play certain roles in transcriptional reg-
ulation (36). However, we did not observe a bypassing of the
intermediate pathway in terms of RA-induced CREB activa-
tion. The role of nuclear PKC remains to be elucidated.
It has been shown that PKC isoforms are differentially ex-
pressed according to the cell types and the differentiational
stages of the same cell linage (19). Other than cPKCs, a novel
PKC has been reported to play an important role in mucin
secretion in airway epithelial cells (45, 62). However, in our
preliminary study, we did not detect any RA-induced phosphor-
ylation of PKC in NHTBE cells (data not shown). Thereafter,
we found that rottlerin, a novel PKC-selective inhibitor, was
not able to inhibit RA-induced PKC phosphorylation and
subsequent CREB activation (Fig. 5B). In contrast, the
cPKC-selective inhibitors GF109203X and Go6976 com-
pletely abolished RA-induced PKC activation and its down-
stream signal transduction (Fig. 5A and Fig. 7B to D), in-
dicating a cPKC-selective activation of RA. Moreover,
treatment with calphostin C, a PKC inhibitor that competes
with diacylglycerol for binding to the C1 domain of PKCs,
did not block the aforementioned activation, which further
supported the model that RA directly activates PKC by
binding to its C2 domain (43).
It is well known that RA activity is mediated mainly through
RAR/RXR. However, our results showed that the activation of
PKC and CREB by RA does not require RAR/RXR. The
functional nullification of RAR/RXR by treatment with pan-
RAR and pan-RXR antagonists or by transfection of siRNAs
targeting RARs and RXR did not block RA-induced activa-
tion of PKC or CREB (Fig. 4). Also, the treatment did not
affect the transactivation activity of CREB in NHTBE cells.
These results clearly demonstrated a nonclassical effect of RA
on the activation of PKC and CREB. We sought to explore
the role of other conventional pathways that are known to
activate PKC or CREB and found that neither PLC (upstream
activator of PKC) nor PKA (upstream activator of CREB) is
required for the RA-induced activation of PKC and CREB
(Fig. 5A).
Our previous study and other previous reports showed that
the downstream signaling of PKC to CREB can be mediated
through the Raf/MEK/ERK/RSK/CREB pathway (1, 29, 46,
FIG. 9. The CRE motif is required for RA-induced MUC5AC promoter activity. NHTBE cells were transiently transfected with a luciferase
expression vector that contained various 5-deleted MUC5AC promoter constructs (A) or with the region from nt 	1366 to 7 of the MUC5AC
promoter construct containing various mutated CRE sites (B). After transfection, cells were treated with 1 M RA or vehicle control (DMSO)
for 48 h, and luciferase activity was the measured. The data were normalized with -gal activity and expressed relative to the basal activity of the
MUC5AC promoter (MUC5AC-LUC [nt 	3752 to 7]  100% [A]; MUC5AC-LUC [nt 	1366 to 7]  100% [B]). Values shown are means 

SE of three independent experiments, each performed with triplicate cultures. , P  0.05; , P  0.01 (compared in pairs between RA-treated
and RA-untreated cultures).
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52). Our results clearly showed that the RA activation of this
signaling pathway was completely blocked in PKC-silenced
NHTBE cells (Fig. 6A), which indicates that PKC is indis-
pensable in this signaling cascade. Our previous studies and the
current one also showed that the RA activation of CREB
requires RSK (CREB kinase) and ERK (RSK kinase); the
knockdown of either ERK or RSK abolished the RA-induced
phosphorylation and transactivation activity of CREB but not
the activation of PKC (Fig. 6B). In addition, our results
clearly showed that RA induced the translocation of RSK but
not ERK from the cytoplasm to the nucleus, implying that
CREB remained in the nucleus and is activated by the trans-
located active RSK (Fig. 7). Our results confirmed that RA-
activated PKC activates the signaling cascade of Raf/MEK/
ERK/RSK/CREB during the mucociliary differentiation of
primary bronchial epithelial cells.
Although we have previously shown that RA induces
MUC5AC gene expression (32), it is not clear whether cis-
regulatory and/or trans-acting factors control the expression of
MUC5AC gene in response to RA. In this study, on the basis of
the promoter reporter assay, we determined that the region
from nt 	1039 to nt 	596 of the MUC5AC promoter is essen-
tial for the response to RA. We found that the CRE motif in
the region at nt 	878 of the MUC5AC promoter is critical for
the RA-induced transcriptional activity of MUC5AC (Fig. 9).
In addition, mutation of the CRE motif sequence abolished
the responsiveness of the MUC5AC promoter reporter to RA.
Further studies employing EMSA and ChIP analyses verified
that RA induced the binding of activated CREB to this puta-
tive CRE motif of the MUC5AC promoter both in vitro and
in vivo. The crucial role of CREB in the transactivation of
MUC5AC was further demonstrated by the silencing of CREB
with siRNA, which abolished the RA-induced transactivation
of the MUC5AC promoter (Fig. 10A). The RA-induced pro-
moter activity of MUC5AC was decreased as the concentration
of transfected CREB siRNA increased, indicating a specific
control of MUC5AC expression by CREB. However, CREB
knockdown abolished not only RA-induced MUC5AC expres-
sion/protein secretion but also the expression of MUC2 and
MUC5B. Using the TFsearch database, we found correspond-
ing putative CRE sites in the MUC2 and MUC5B promoter
regions (Fig. 12B). Taken together, these results strongly sug-
gest that CREB is a potent transcriptional regulator of several
mucin genes, including MUC2, MUC5AC, and MUC5B, in hu-
man primary airway epithelial cells.
In agreement with our findings in the current study, it was
previously shown that CRE is critical for interleukin-1- and
tumor necrosis factor alpha-induced MUC5AC upregulation
in normal human nasal epithelial cells and the NCI-H292
human mucoepidermoid cell line and that the ERK/RSK/
CREB signaling pathway is responsible for mediating the
resultant MUC5AC promoter activation (56). Correspond-
ingly, CREB has also been shown to regulate MUC8 gene
expression induced by prostaglandin E2 and interleukin-1
via the same signaling pathway (6, 57). In addition, the
Raf/MEK/ERK pathway has been reported to plays an im-
portant role in regulating lipopolysaccharide- and epidermal
growth factor (EGF)-induced mucin expression in airway
epithelia, especially in the situation of mucin overproduc-
tion (33, 54, 60). These results, in concert, suggest that the
CRE motif and CREB signaling pathway activated by in-
flammatory mediators are important in the up-regulation of
secretory mucins. It is conceivable that the cross talk among
signaling pathways activated by RA, inflammatory media-
tors, and growth factors is critical for modulating mucin
expression under physiological and pathological conditions.
Moreover, in the absence of RA, high concentrations of
EGF cause squamous metaplasia instead of mucin overpro-
duction (our unpublished observation). This indispensable-
ness of RA in mucous differentiation suggests that the rapid
FIG. 10. RA induced a specific interaction between CREB and
CRE sites on the MUC5AC promoter. NHTBE cells were cultured
for 7 days with or without RA. (A) Nuclear extracts were prepared,
and DNA-protein binding activity was measured by EMSA using
various [-32P]ATP-labeled oligonucleotides (as indicated in Fig.
9B) that corresponded to nt 	886 to nt 	863 in the MUC5AC
promoter. The DNA-binding reaction was performed in the absence
or presence of a 100-fold excess (100) of unlabeled oligonucleo-
tides (as an unlabeled competitor). Supershift assays were per-
formed using 2 g of the anti-CREB and anti-pCREB antibodies
(Ab), as indicated above each lane. The labeled nucleotide and
nuclear protein complexes were separated by electrophoresis on 5%
polyacrylamide gels and subjected to autoradiography. The arrow-
head with the asterisk indicates shifted bands. (B) ChIP analysis.
NHTBE cells were treated with 1 M RA for 4 h, and ChIP assays
were then performed using anti-CREB and anti-pCREB to precip-
itate MUC5AC promoter regions (nt 	980 to nt 	708) as described
in Materials and Methods. As a positive control, 1% of the chro-
matin was assayed to verify equal loading (Input). Nonspecific IgG
(Control IgG) was assayed under otherwise identical conditions as
a negative control. Results shown are representative of three inde-
pendent experiments. IP, immunoprecipitation.
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activation of CREB by RA via the PKC/Raf/MEK/ERK/
RSK signaling pathway has a priming effect on MUC5AC
production and mucous differentiation in primary bronchial
epithelial cells.
In summary, we demonstrated a nonclassical signaling
pathway by which RA activates CREB. We showed that RA
activates the PKC isozyme and that RA-activated PKC
immediately translocates from the cytoplasm to the plasma
and perinuclear membranes and transmits activation signals
to CREB via the activation of a linear signaling cascade,
Raf/MEK/ERK/RSK, without using conventional RAR and
RXR in primary bronchial epithelial cells. Activated RSK
was then translocated from the cytoplasm to the nucleus,
where it activates CREB and where the activated CREB
transactivates the MUC5AC gene. On the basis of our cur-
rent and previous findings, we propose a new paradigm for
RA-induced mucociliary differentiation of bronchial epithe-
lial cells in which the nonclassical action (mediated through
CREB) and the conventional action (mediated through
RAR and RXR) of RA each assume important physiological
FIG. 11. CREB is required for RA-induced expression of MUC5AC, MUC2, and MUC5B. (A) NHTBE cells were transiently cotransfected with
a luciferase expression vector that contained the region from nt 	1366 to 7 of the MUC5AC promoter construct and various concentrations of
CREB siRNA (CREB-siRNA) (as indicated) or 100 nM nonspecific control pool (NS-siRNA). After transfection, cells were treated with 1 M
RA or vehicle control (DMSO) for 72 h, and luciferase activity was then measured. 8-Br-cAMP (1 M) was used as a positive control for the CREB
activator. The data were normalized according to -gal activity. (B and C) NHTBE cells were transiently transfected with 100 nM CREB siRNA
or nonspecific control siRNA. Three days after transfection, the cells were incubated with or without 1 M RA or vehicle control (DMSO) for
another 24 h, and MUC5AC mRNA expression and MUC5AC protein secretion were then analyzed. (D) CREB protein expression was measured
as a control for the siRNA experiments. After treatment, MUC2 (E) and MUC5B (G) mRNA expression levels were analyzed. (G) CREB mRNA
expression was measured to determine the siRNA transfection efficiency. Values are means 
 SE of triplicate independent experiments, each
performed with triplicate cultures. , P  0.05; , P  0.01 (compared with RA-untreated control). †, P  0.05; ††, P  0.01 (compared with the
nonspecific control siRNA-transfected group).
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roles and cooperatively facilitate the differentiation of bron-
chial epithelia.
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